









市場行情
/
股票
/
nasdaq-bcyc
/

Bicycle Therapeutics PLC

BCYC

6.950USD

-0.240-3.34%

交易中（美東）報價延遲15分鐘

346.59M總市值

虧損本益比TTM



Bicycle Therapeutics PLC

6.950

-0.240-3.34%

概覽公司財務分析

概覽

公司

財務

分析

關於 Bicycle Therapeutics PLC 公司

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics PLC簡介



公司代碼BCYC

公司名稱Bicycle Therapeutics PLC

上市日期May 23, 2019

CEOLee (Kevin)

員工數量305

證券類型Depository Receipt

年結日May 23

公司地址Blocks A & B, Portway Building

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編CB21 6GS

電話11441223261503

網址https://www.bicycletherapeutics.com/

公司代碼BCYC

上市日期May 23, 2019

CEOLee (Kevin)

Bicycle Therapeutics PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Kevin Lee, Ph.D.

Chief Executive Officer, Executive Director

275.59K

-23.43%

Dr. Michael Skynner, Ph.D.

Chief Technology Officer

72.92K

+73.03%

Mr. Alistair Milnes

Chief Operating Officer

25.33K

-65.69%

Ms. Janice Bourque

Non-Executive Independent Director

18.31K

+49.49%

Charles Swanton

Independent Director

Dr. Roger D. Dansey, M.D.

Independent Director

Mr. Herve Hoppenot

Independent Director

Mr. Eric Westin, M.D.

Chief Medical Officer

Dr. Alessandro Riva, M.D.

Non-Executive Independent Director

Mr. Stephen Sands

Non-Executive Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Kevin Lee, Ph.D.

Chief Executive Officer, Executive Director

275.59K

-23.43%

Dr. Michael Skynner, Ph.D.

Chief Technology Officer

72.92K

+73.03%

Mr. Alistair Milnes

Chief Operating Officer

25.33K

-65.69%

Ms. Janice Bourque

Non-Executive Independent Director

18.31K

+49.49%

Charles Swanton

Independent Director

Dr. Roger D. Dansey, M.D.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

21.80%

Forbion Capital Partners

6.91%

Armistice Capital LLC

5.96%

Westfield Capital Management Company, L.P.

5.91%

Invus Public Equities Advisors, LLC

4.03%

其他

55.38%

持股股東

佔比

Baker Bros. Advisors LP

21.80%

Forbion Capital Partners

6.91%

Armistice Capital LLC

5.96%

Westfield Capital Management Company, L.P.

5.91%

Invus Public Equities Advisors, LLC

4.03%

其他

55.38%

股東類型

持股股東

佔比

Hedge Fund

37.45%

Investment Advisor

15.62%

Investment Advisor/Hedge Fund

14.44%

Venture Capital

7.08%

Research Firm

3.61%

Individual Investor

1.59%

Pension Fund

0.49%

Family Office

0.25%

其他

19.47%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

242

39.22M

114.58%

+31.05K

2025Q3

266

40.06M

126.53%

-4.18M

2025Q2

264

44.22M

123.05%

-338.39K

2025Q1

249

44.93M

127.83%

-16.05M

2024Q4

249

44.97M

130.44%

+273.71K

2024Q3

245

43.83M

123.27%

+876.01K

2024Q2

237

43.44M

106.75%

+5.72M

2024Q1

253

34.16M

113.53%

-14.25M

2023Q4

258

34.56M

124.36%

-3.64M

2023Q3

255

38.68M

90.77%

+8.35M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

10.89M

21.83%

Jun 30, 2025

Forbion Capital Partners

3.45M

6.92%

Jun 30, 2025

Armistice Capital LLC

2.80M

5.61%

+128.00K

+4.79%

Jun 30, 2025

Westfield Capital Management Company, L.P.

2.78M

5.58%

+123.19K

+4.64%

Jun 30, 2025

Invus Public Equities Advisors, LLC

2.01M

4.04%

+200.00K

+11.03%

Jun 30, 2025

Long Focus Capital Management LLC

1.32M

2.64%

+23.54K

+1.82%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.47M

2.94%

-68.19K

-4.44%

Jun 30, 2025

Candriam Luxembourg S.A.

1.32M

2.65%

Aug 31, 2025

Acadian Asset Management LLC

698.50K

1.4%

+572.44K

+454.09%

Jun 30, 2025

Candriam Belgium S.A.

1.17M

2.35%

-32.82K

-2.72%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

0.63%

Invesco NASDAQ Future Gen 200 ETF

0.59%

Harbor Health Care ETF

0.23%

ALPS Medical Breakthroughs ETF

0.17%

iShares Health Innovation Active ETF

0.05%

Invesco Nasdaq Biotechnology ETF

0.04%

ProShares Ultra Nasdaq Biotechnology

0.04%

SPDR S&P International Small Cap ETF

0.03%

iShares Biotechnology ETF

0.02%

ActivePassive International Equity ETF

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.63%

Invesco NASDAQ Future Gen 200 ETF

佔比0.59%

Harbor Health Care ETF

佔比0.23%

ALPS Medical Breakthroughs ETF

佔比0.17%

iShares Health Innovation Active ETF

佔比0.05%

Invesco Nasdaq Biotechnology ETF

佔比0.04%

ProShares Ultra Nasdaq Biotechnology

佔比0.04%

SPDR S&P International Small Cap ETF

佔比0.03%

iShares Biotechnology ETF

佔比0.02%

ActivePassive International Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Bicycle Therapeutics PLC的前五大股東是誰？



Bicycle Therapeutics PLC的前五大股東如下：
Baker Bros. Advisors LP
持有股份：10.89M
佔總股份比例：21.83%。
Forbion Capital Partners
持有股份：3.45M
佔總股份比例：6.92%。
Armistice Capital LLC
持有股份：2.80M
佔總股份比例：5.61%。
Westfield Capital Management Company, L.P.
持有股份：2.78M
佔總股份比例：5.58%。
Invus Public Equities Advisors, LLC
持有股份：2.01M
佔總股份比例：4.04%。